

Special Issue

Kinases and Other Molecular Targets in Cancer: Recent Advances, Therapeutic Opportunities, and Clinical Challenges

Message from the Guest Editor

Kinases play a diverse role in regulating cellular processes, including proliferation, differentiation, and apoptosis. However, deregulation of kinase activity can result in oncogenic changes that enable cellular transformation, tumor development, and metastasis. This may occur due to the acquisition of mutations, constitutive expression and/or amplification, epigenetic alterations, and chromosomal translocations. Kinase inhibitors have revolutionized the treatment landscape of numerous malignancies, including melanoma and non-small-cell lung cancer. However, these drugs are not curative and only a minority of patients derive durable clinical benefit. For this reason, gaining deeper insights into the immunological and molecular mechanisms that underpin therapeutic resistance to kinase inhibitors remains a prime focus in oncology. This Special Issue will publish original research and reviews.

Guest Editor

Dr. Ashleigh Poh

The Olivia Newton-John Cancer Research Institute, Level 5, ONJ Centre, 145 Studley Rd, Heidelberg, VIC 3084, Australia

Deadline for manuscript submissions

closed (30 November 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/125020

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).